Interv Akut Kardiol. 2020;19(1):48-52 | DOI: 10.36290/kar.2020.018

Antithrombotic therapy after percutaneous and surgical interventions on valves

Marian Branny
Kardiocentrum, Fakultní nemocnice Ostrava

Surgical and catheter interventions on stenotic or insufficient valves are the only acknowledged effective treatment for patients with a haemodynamically significant defect. Interventional valve repair carries a risk of both thrombotic and bleeding complications. Although antithrombotic drugs reduce the risks of interventional treatment, an optimal therapeutic regimen and treatment duration remain unknown. This article presents an overview of recent information on this issue as well as a review of current evidence on antithrombotic therapy following interventional treatment for valvular heart disease.

Keywords: valvular heart disease, antithrombotic drugs, surgical valve replacement, catheter valve replacement, Mitra Clip.

Published: June 1, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Branny M. Antithrombotic therapy after percutaneous and surgical interventions on valves. Interv Akut Kardiol. 2020;19(1):48-52. doi: 10.36290/kar.2020.018.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Iung B, Vahanian A. Epidemiology of acquired valvular heart disease. Can J Cardiol 2014; 30: 962-970. Go to original source... Go to PubMed...
    2. Leon MB, Smith CR, Mack M, et al.; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010; 363: 1597-1607. Go to original source... Go to PubMed...
    3. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of the patients with valvular heart disease: a report of the AHA/ACC Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017; 70, 252-289. Go to original source...
    4. Baumgartner H, Falk V, Bax JJ, et al.; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017; 38: 2739-2791. Go to original source... Go to PubMed...
    5. Mack MJ, Leon MB, Thourani VH, et al.; PARTNER 3 Investigators. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 2019; 380: 1695-1705. Go to original source... Go to PubMed...
    6. Popma JJ, Deeb GM, Yakubov SJ, et al.; Evolut Low Risk Trial Investigators. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 2019; 380: 1706-1715. Go to original source... Go to PubMed...
    7. Vranckx P, Windecker S, Welsh RC, et al. Thromboembolic prevention after transcatheter aortic valve implantation. Eur Heart J 2017; 38: 3341-3350. Go to original source... Go to PubMed...
    8. Gurvitch R, Toggweiler S, Willson AB, et al. Outcomes and complications of transcatheter aortic valve replacement using a balloon expandable valve according to the Valve Academic Research Consortium (VARC) guidelines. EuroIntervention 2011; 7: 41-48. Go to original source... Go to PubMed...
    9. Généreux P, Cohen DJ, Mack M, et al. Incidence, predictors, and prognostic impact of late bleeding complications after transcatheter aortic valve replacement. J Am Coll Cardiol 2014; 64: 2605-2615. Go to original source...
    10. Agnihotri A; American Association for Thoracic Surgery; American College of Cardiology Foundation; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: executive summary. J Thorac Cardiovasc Surg 2012; 144: 534-537. Go to original source...
    11. Puri R, Altisent OA, Campelo-Parada F, et al. Balancing the risks of thrombosis and bleeding following transcatheter aortic valve implantation: current state-of-evidence. Curr Pharm Des 2016; 22: 1904-1910. Go to original source...
    12. Cerrato E, Nombela-Franco L, Nazif TM, et al. Evaluation of current practices in transcatheter aortic valve implantation: the WRITTEN (WoRldwIde TAVI ExperieNce) survey. Int J Cardiol 2017; 228: 640-647. Go to original source...
    13. Ussia GP, Scarabelli M, Mulè M, et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 2011; 108: 1772-1726. Go to original source...
    14. Stabile E, Pucciarelli A, Cota L, et al. SAT-TAVI (single antiplatelet therapy for TAVI) study: a pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation. Int J Cardiol 2014; 174: 624-627. Go to original source...
    15. Rodés-Cabau J, Masson JB, Welsh RC, et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon expandable valve: the ARTE (Aspirin versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) randomized clinical trial. JACC Cardiovasc Interv 2017; 10: 1357-1365. Go to original source... Go to PubMed...
    16. Maes F, Stabile E, Ussia GP, et al. Meta-analysis comparing single versus dual antiplatelet therapy following transcatheter aortic valve implantation. Am J Cardiol 2018; 122: 310-315. Go to original source...
    17. Nijenhuis VJ, Bennaghmouch N, Hassel M, et al. Rationale and design of POPular-TAVI: antiplatelet therapy for patients undergoing transcatheter aortic valve implantation. Am Heart J 2016; 173: 77-85. Go to original source... Go to PubMed...
    18. Dangas GD, Tijssen JP, Wöhrle J, et al.; GALILEO Investigators. A controlled trial of rivaroxaban after transcatheter aortic valve replacement. N Engl J Med 2019; Nov 16. doi: 10.1056/NEJMoa1911425. Go to original source...
    19. Chopard R, Teiger E, Meneveau N, et al.; FRANCE-2 Investigators. Baseline characteristics and prognostic implications of pre-existing and new onset atrial fibrillation after transcatheter aortic valve implantation: results from the FRANCE-2 registry. JACC Cardiovasc Interv 2015; 8: 1346-1355. Go to original source... Go to PubMed...
    20. Vora AN, Dai D, Matsuoka R, et al. Incidence, management, and associated clinical outcomes of new-onset atrial fibrillation following transcatheter aortic valve replacement: an analysis from the STS/ACC TVT registry. JACC Cardiovasc Interv 2018; 11: 1746-1756. Go to original source... Go to PubMed...
    21. Tarantini G, Mojoli M, Windecker S, et al. Prevalence and impact of atrial fibrillation in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis from the SOURCE XT prospective multicenter registry. JACC Cardiovasc Interv 2016; 9: 937-946. Go to original source... Go to PubMed...
    22. Banovic M, Iung B, Bartunek J, et al. Rationale and design of the Aortic Valve replAcemenT versus conservative treatment in Asymptomatic seveRe aortic stenosis (AVATAR trial): a randomized multicenter controlled event-driven trial. Am Heart J 2016; 174: 147-153. Go to original source... Go to PubMed...
    23. Collet JP, Berti S, Cequier A, et al. Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: the randomized ATLANTIS trial. Am Heart J 2018; 200: 44-50. Go to original source... Go to PubMed...
    24. Van Mieghem NM, Unverdorben M, Valgimigli M, et al. EdoxabaN Versus standard of care and theIr effectS on clinical outcomes in pAtients havinG undergonE Transcatheter Aortic Valve Implantation in Atrial Fibrillation - rationale and design of the ENVISAGETAVI AF trial. Am Heart J 2018; 205: 63-69. Go to original source... Go to PubMed...
    25. Gafoor S, Heuer L, Franke J, et al. Transcatheter aortic valve replacement and left atrial appendage occlusion - a stitch in time? Interv Cardiol Rev 2014; 9: 126-129. Go to original source...
    26. Bogunovic N, Scholtz W, Prinz C, et al. Percutaneous closure of left atrial appendage after transcatheter aortic valve implantation - an interventional approach to avoid anticoagulation therapy in elderly patients: TAVI and closure of LAA to avoid warfarin therapy. EuroIntervention 2012; 7: 1361-1363. Go to original source... Go to PubMed...
    27. Chakravarty T, Søndergaard L, Friedman J, et al.; RESOLVE; SAVORY Investigators. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet 2017; 389: 2383-2392. Go to original source...
    28. Iung B, Rodes-Cabau J. The optimal management of anti-thrombotic therapy after valve replacement: certainties and uncertainties. Eur Heart J 2014; 35: 2942-2949. Go to original source... Go to PubMed...
    29. Rivas-Gándara N, Ferreira-González I, Tornos P, et al. Enoxaparin as bridging anticoagulant treatment in cardiac surgery. Heart 2008; 94: 205-210. Go to original source...
    30. Cannegieter SC, Rosendaal FR, Briët E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994; 89: 635-641. Go to original source...
    31. Mok CK, Boey J, Wang R, et al. Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial. Circulation 1985; 72: 1059-1063. Go to original source...
    32. Eikelboom JW, Connolly SJ, Brueckmann M, et al.; RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369: 1206-1214. Go to original source...
    33. Laffort P, Roudaut R, Roques X, et al. Early and long-term (one-year) effects of the association of aspirin and oral anticoagulant on thrombi and morbidity after replacement of the mitral valve with the St. Jude medical prosthesis: a clinical and transesophageal echocardiographic study. J Am Coll Cardiol 2000; 35: 739-746. Go to original source...
    34. Brennan JM, Edwards FH, Zhao Y, et al.; DEcIDE AVR Research Team. Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. J Am Coll Cardiol 2012; 60: 971-977. Go to original source...
    35. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17: 1467-1507. Go to original source... Go to PubMed...
    36. Maisano F, Franzen O, Baldus S, et al. Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. J Am Coll Cardiol 2013; 62: 1052-1061. Go to original source...
    37. Mauri L, Foster E, Glower DD, et al.; EVEREST II Investigators. 4-year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation. J Am Coll Cardiol 2013; 62: 317-328. Go to original source...
    38. Stone GW, Lindenfeld JA, Abraham WT, et al. COAPT Investigators. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 2018; 379: 2307-2318. Go to original source...
    39. Obadia JF, Messika-Zeitoun D, Leurent G, et al. MITRA-FR Investigators. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med 2018; 379: 2297-2306. Go to original source...
    40. Chakravarty T, Sondegaard L, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet 2017; 389: 2383-2392. Go to original source...
    41. Puri R, Auffret V, Rodes-Cabau J. Bioprosthetic valve thrombosis. J Am Coll Cardiol 2017; 69: 2193-2211. Go to original source...
    42. Mazine A, Verma S, Yanagawa B. Early failure of aortic bioprostheses. Curr Opin Cardiol. 2019; 34: 173-7. Go to original source... Go to PubMed...
    43. Sondergaard L, De Backer O, et al. Natural history of subclinical leaflet thrombosis affectingmotion in bioprosthetic aortic valves. Eur Heart J. 2017; 38: 2201-7. Go to original source... Go to PubMed...
    44. Barbanti M, Costa G, Zappulla P, Todaro D, Picci A, Rapisarda G, et al. Incidence of long-term structural valve dysfunction and bioprosthetic valve failure after transcatheter aortic valve replacement. J Am Heart Assoc. 2018: 7. Go to original source...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.